Moderna's stock surged after announcing that trial data for its individualized neoantigen therapy, intismeran, will be presented at the European Society for Medical Oncology (ESMO) Congress 2026. This news, particularly the Phase 3 trial data for melanoma, is driving significant investor interest and positive price action.
Moderna (MRNA) shares are trending and saw a significant jump in the regular session, continuing into after-hours, due to the announcement that three abstracts on its investigational mRNA-based individualized neoantigen therapy, intismeran, have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026. The lead abstract details Phase 3 trial data for intismeran in combination with Merck's (MRK) pembrolizumab for melanoma patients, which is a major catalyst for the stock. This news signals potential progress in a key therapeutic area, offering a significant short-term opportunity for traders betting on positive clinical developments and long-term implications for Moderna's pipeline and market position in oncology. The stock's current position near its annual high and strong momentum indicate high investor confidence.